
CNTB Stock Forecast & Price Target
CNTB Analyst Ratings
Bulls say
Connect Biopharma Hldgs is well-positioned for success with in-depth partnerships, promising trial results, and a large potential market for their medication. Key factors such as upcoming tests and potential FDA acceptance will determine the future success of the medication in the market. Disciplined financial planning and partnerships have also given the company a strong foundation for growth and potential commercialization of their medication.
Bears say
Connect Biopharma Hldgs is a high-risk investment due to its heavy reliance on a small clinical dataset, third-party manufacturing, and other typical risks associated with a single-asset clinical-stage biotech company. The company's main revenue driver, its rademikibart drug, is largely unproven and still in clinical trials for treatment of asthma and COPD exacerbations. Additionally, there is uncertainty surrounding the company's ability to finance its Phase 3 program without diluting shares. Overall, these factors contribute to a negative outlook on Connect Biopharma Hldgs' stock.
This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.
CNTB Analyst Forecast & Price Prediction
Start investing in CNTB
Order type
Buy in
Order amount
Est. shares
0 shares